Medicina
Departamento
University of Washington School of Medicine
Seattle, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Washington School of Medicine (27)
2024
-
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study
Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306
2023
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437
-
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
European Urology
-
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
European Journal of Cancer
-
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience
Clinical Genitourinary Cancer, Vol. 21, Núm. 5, pp. 584-593
2022
-
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 20, Núm. 5, pp. e440-e452
-
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
BJU International, Vol. 130, Núm. 5, pp. 592-603
-
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 20, Núm. 6, pp. 558-567
-
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
New England Journal of Medicine, Vol. 386, Núm. 4, pp. 305-315
-
Grade 3 coronary artery perforations in chronic total occlusion-percutaneous coronary intervention: Mechanisms, locations, and outcomes from the G3CAP Registry
Catheterization and Cardiovascular Interventions, Vol. 100, Núm. 2, pp. 190-198
-
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060
-
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
Clinical Genitourinary Cancer, Vol. 20, Núm. 2, pp. 165-175
-
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Annals of Oncology, Vol. 33, Núm. 11, pp. 1168-1178
2021
-
21-gene assay to inform chemotherapy benefit in node-positive breast cancer
New England Journal of Medicine, Vol. 385, Núm. 25, pp. 2336-2347
-
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
European urology oncology, Vol. 4, Núm. 3, pp. 464-472
-
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
The Lancet Respiratory Medicine, Vol. 9, Núm. 12, pp. 1407-1418
-
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
BJU International, Vol. 128, Núm. 2, pp. 196-205
-
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
The Lancet Oncology, Vol. 22, Núm. 7, pp. 959-969
-
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma
The Journal of urology, Vol. 205, Núm. 2, pp. 414-419
2019
-
Equalization of four cardiovascular risk algorithms after systematic recalibration: Individual-participant meta-analysis of 86 prospective studies
European Heart Journal, Vol. 40, Núm. 7, pp. 621-631